{
    "xml": "<topic id=\"PHP1529\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/abciximab\" basename=\"abciximab\" title=\"ABCIXIMAB\">\n<title>ABCIXIMAB</title>\n<body>\n<data name=\"vtmid\">108974006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872314852\" title=\"Glycoprotein IIb/IIIa inhibitors\">Glycoprotein IIb/IIIa inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP67768\" outputclass=\"indicationsAndDose\" rev=\"1.17\" parent=\"/drugs/abciximab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 250&#8239;micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125&#8239;nanograms/kg/minute (max. per dose 10&#8239;micrograms/minute), to be started 10&#8211;60 minutes before percutaneous coronary intervention and continue for 12 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 250&#8239;micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125&#8239;nanograms/kg/minute (max. per dose 10&#8239;micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67855\" outputclass=\"contraindications\" rev=\"1.15\" parent=\"/drugs/abciximab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active internal bleeding</ph>; <ph outputclass=\"contraindication\">arteriovenous malformation or aneurysm</ph>; <ph outputclass=\"contraindication\">haemorrhagic diathesis</ph>; <ph outputclass=\"contraindication\">hypertensive retinopathy</ph>; <ph outputclass=\"contraindication\">intracranial neoplasm</ph>; <ph outputclass=\"contraindication\">intracranial or intraspinal surgery or trauma within last 2 months</ph>; <ph outputclass=\"contraindication\">major surgery within last 2 months</ph>; <ph outputclass=\"contraindication\">severe hypertension</ph>; <ph outputclass=\"contraindication\">stroke within last 2 years</ph>; <ph outputclass=\"contraindication\">thrombocytopenia</ph>; <ph outputclass=\"contraindication\">vasculitis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67896\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/abciximab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimise bleeding)</ph>; <ph outputclass=\"caution\">elderly</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67759\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/abciximab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67684\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/abciximab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Back pain</ph>; <ph outputclass=\"sideEffect\">bleeding manifestations</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">chest pain</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">puncture site pain</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Adult respiratory distress</ph>; <ph outputclass=\"sideEffect\">cardiac tamponade</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67750\" outputclass=\"pregnancy\" parent=\"/drugs/abciximab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67933\" outputclass=\"breastFeeding\" parent=\"/drugs/abciximab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67788\" outputclass=\"hepaticImpairment\" parent=\"/drugs/abciximab\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe liver disease&#8212;increased risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67723\" outputclass=\"renalImpairment\" parent=\"/drugs/abciximab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in severe impairment&#8212;increased risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67641\" outputclass=\"monitoringRequirements\" parent=\"/drugs/abciximab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin and haematocrit.</p>\n<p>Monitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2&#8211;4 hours and 24 hours after start of treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1529-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/abciximab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77285\" title=\"Solution for injection\" namespace=\"/drugs/abciximab/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"1\" rel=\"backlink\">Acute coronary syndromes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78186\" namespace=\"/treatment-summaries/antiplatelet-drugs\" title=\"Antiplatelet drugs\" count=\"3\" rel=\"backlink\">Antiplatelet drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77285\" namespace=\"/drugs/abciximab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1529",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/abciximab",
    "basename": "abciximab",
    "title": "ABCIXIMAB",
    "vtmid": "108974006",
    "drugClassification": [
        "Glycoprotein IIb/IIIa inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (specialist use only)",
                        "html": "Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. per dose 10 micrograms/minute), to be started 10&#8211;60 minutes before percutaneous coronary intervention and continue for 12 hours.",
                        "html": "<p>Initially 250&#8239;micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125&#8239;nanograms/kg/minute (max. per dose 10&#8239;micrograms/minute), to be started 10&#8211;60 minutes before percutaneous coronary intervention and continue for 12 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (specialist use only)",
                        "html": "Short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. per dose 10 micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention.",
                        "html": "<p>Initially 250&#8239;micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125&#8239;nanograms/kg/minute (max. per dose 10&#8239;micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active internal bleeding",
                "html": "Active internal bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "arteriovenous malformation or aneurysm",
                "html": "arteriovenous malformation or aneurysm"
            },
            {
                "type": "contraindications",
                "textContent": "haemorrhagic diathesis",
                "html": "haemorrhagic diathesis"
            },
            {
                "type": "contraindications",
                "textContent": "hypertensive retinopathy",
                "html": "hypertensive retinopathy"
            },
            {
                "type": "contraindications",
                "textContent": "intracranial neoplasm",
                "html": "intracranial neoplasm"
            },
            {
                "type": "contraindications",
                "textContent": "intracranial or intraspinal surgery or trauma within last 2 months",
                "html": "intracranial or intraspinal surgery or trauma within last 2 months"
            },
            {
                "type": "contraindications",
                "textContent": "major surgery within last 2 months",
                "html": "major surgery within last 2 months"
            },
            {
                "type": "contraindications",
                "textContent": "severe hypertension",
                "html": "severe hypertension"
            },
            {
                "type": "contraindications",
                "textContent": "stroke within last 2 years",
                "html": "stroke within last 2 years"
            },
            {
                "type": "contraindications",
                "textContent": "thrombocytopenia",
                "html": "thrombocytopenia"
            },
            {
                "type": "contraindications",
                "textContent": "vasculitis",
                "html": "vasculitis"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimise bleeding)",
                "html": "Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimise bleeding)"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Caution with concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Back pain",
                        "html": "Back pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bleeding manifestations",
                        "html": "bleeding manifestations",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "chest pain",
                        "html": "chest pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "puncture site pain",
                        "html": "puncture site pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Adult respiratory distress",
                        "html": "Adult respiratory distress",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "cardiac tamponade",
                        "html": "cardiac tamponade",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe liver disease&#8212;increased risk of bleeding.",
                "html": "<p>Avoid in severe liver disease&#8212;increased risk of bleeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in severe impairment&#8212;increased risk of bleeding.",
                "html": "<p>Caution in severe impairment&#8212;increased risk of bleeding.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin and haematocrit.\n\nMonitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2&#8211;4 hours and 24 hours after start of treatment.",
                "html": "<p>Measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin and haematocrit.</p><p>Monitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2&#8211;4 hours and 24 hours after start of treatment.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77285",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78186",
                "label": "Antiplatelet drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77285",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}